Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients

Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients

Bisphosphonates are well known inhibitors of osteoclast activity and thus may be employed to influence osteoblast activity. The present study was designed to evaluate the in vivo effects of zoledronic acid (ZA) on the proliferation and osteoblastic commitment of mesenchymal stem cells (MSC) in osteo...

Full description

Bibliographic Details
Main Authors: Luca Dalle Carbonare, Monica Mottes, Giovanni Malerba, Antonio Mori, Martina Zaninotto, Mario Plebani, Alessandra Dellantonio, Maria Teresa Valenti
Format: Article
Language:English
Published: MDPI AG 2017-06-01
Series:International Journal of Molecular Sciences
Subjects:
mesenchymal stem cells
Runt-related transcription factor 2 (RUNX2)
zoledronic acid
gene expression
bone turnover
differentiation
Online Access:http://www.mdpi.com/1422-0067/18/6/1261

Internet

http://www.mdpi.com/1422-0067/18/6/1261

Similar Items